Degradation of the anticancer drug erlotinib during water chlorination: Non-targeted approach for the identification of transformation products

Water Research

Volumn 85, Issue , 2015, Pages 103-113

  Negreira, Noelia ^a   Regueiro, Jorge ^b   López de Alda, Miren ^a   Barceló, Damià ^a,c  

^a INSTITUTE OF ENVIRONMENTAL ASSESSMENT AND WATER RESEARCH   (Spain)

^b UNIVERSITY OF VIGO   (Spain)

^c UNIVERSITY OF GIRONA   (Spain)

Author keywords

Cytostatic drugs; Degradation; Free chlorine; Orbitrap; Reactivity; Untargeted

Indexed keywords

AMINO ACIDS; AQUATIC ORGANISMS; CHLORINATION; CHLORINE; DRUG PRODUCTS; EFFLUENTS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; WASTEWATER TREATMENT;

ANTICANCER DRUG; CYTOSTATIC; CYTOSTATIC DRUG; ERLOTINIB; FREE CHLORINE; NON-TARGETED; ORBITRAP; REACTIVITY; TRANSFORMATION PRODUCTS; UNTARGETED;

TOXICITY;

CHLORINE; ERLOTINIB; ANTINEOPLASTIC AGENT; DISINFECTANT AGENT; WATER POLLUTANT;

AQUATIC ORGANISM; BIODEGRADATION; BIOTRANSFORMATION; CANCER; CHLORINATION; CHLORINE; DISEASE TREATMENT; DRUG; HYDROXYL RADICAL; IDENTIFICATION METHOD; OXIDATION; TOXICOLOGY;

ARTICLE; CHEMICAL STRUCTURE; CHLORINATION; DATA BASE; DRUG DEGRADATION; HYDROXYLATION; MEASUREMENT ERROR; OXIDATION; PRIORITY JOURNAL; REACTION TIME; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WASTE WATER TREATMENT PLANT; WATER SAMPLING; ANALYSIS; CHEMISTRY; HALOGENATION; LIQUID CHROMATOGRAPHY; PROCEDURES; SEWAGE; TANDEM MASS SPECTROMETRY; WATER POLLUTANT;

ANTINEOPLASTIC AGENTS; CHLORINE; CHROMATOGRAPHY, LIQUID; DISINFECTANTS; ERLOTINIB HYDROCHLORIDE; HALOGENATION; TANDEM MASS SPECTROMETRY; WASTE DISPOSAL, FLUID; WATER POLLUTANTS, CHEMICAL;

EID: 84939619770     PISSN: 00431354     EISSN: 18792448     Source Type: Journal    
DOI: 10.1016/j.watres.2015.08.005     Document Type: Article

References (34)

1. Bedner M., MacCrehan W.A. Transformation of acetaminophen by chlorination produces the toxicants 1,4-benzoquinone and N-acetyl-p-benzoquinone imine. Environ. Sci. Technol. 2006, 40(2):516-522.
2. Besse J.-P., Latour J.-F., Garric J. Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?. Environ. Int. 2012, 39(1):73-86.
3. Bletsou A.A., Jeon J., Hollender J., Archontaki E., Thomaidis N.S. Targeted and non-targeted liquid chromatography-mass spectrometric workflows for identification of transformation products of emerging pollutants in the aquatic environment. Trac. Trends Anal. Chem. 2015, 66(0):32-44.
4. Bourgin M., Bichon E., Antignac J.-P., Monteau F., Leroy G., Barritaud L., Chachignon M., Ingrand V., Roche P., Le Bizec B. Chlorination of bisphenol A: non-targeted screening for the identification of transformation products and assessment of estrogenicity in generated water. Chemosphere 2013, 93(11):2814-2822.
5. Canosa P., Rodríguez I., Rubí E., Negreira N., Cela R. Formation of halogenated by-products of parabens in chlorinated water. Anal. Chim. Acta 2006, 575(1):106-113.
6. Clesceri L.S., Greenberg A.E., Eaton A.D. Standard Methods for the Examination of Water and Wastewater 1998, 461-465. American Water Works Association, Maryland. twentieth ed.
7. Ferrando-Climent L., Rodriguez-Mozaz S., Barceló D. Development of a UPLC-MS/MS method for the determination of ten anticancer drugs in hospital and urban wastewaters, and its application for the screening of human metabolites assisted by information-dependent acquisition tool (IDA) in sewage samples. Anal. Bioanal. Chem. 2013, 405(18):5937-5952.
8. Ferrando-Climent L., Rodriguez-Mozaz S., Barceló D. Incidence of anticancer drugs in an aquatic urban system: from hospital effluents through urban wastewater to natural environment. Environ. Pollut. 2014, 193(0):216-223.
9. Jones, O.H., Voulvoulis N., Lester J. Human pharmaceuticals in wastewater treatment processes. Crit. Rev. Environ. Sci. Technol. 2005, 35(4):401-427.
10. Joss A., Keller E., Alder A.C., Göbel A., McArdell C.S., Ternes T., Siegrist H. Removal of pharmaceuticals and fragrances in biological wastewater treatment. Water Res. 2005, 39(14):3139-3152.
11. Kessner D., Chambers M., Burke R., Agus D., Mallick P. ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics 2008, 24(21):2534-2536.
12. Köhler C., Venditti S., Igos E., Klepiszewski K., Benetto E., Cornelissen A. Elimination of pharmaceutical residues in biologically pre-treated hospital wastewater using advanced UV irradiation technology: a comparative assessment. J. Hazard. Mater. 2012, 239-240(0):70-77.
13. Kosjek T., Heath E. Occurrence, fate and determination of cytostatic pharmaceuticals in the environment. Trac. Trends Anal. Chem. 2011, 30(7):1065-1087.
14. Krauss M., Singer H., Hollender J. LC-high resolution MS in environmental analysis: from target screening to the identification of unknowns. Anal. Bioanal. Chem. 2010, 397(3):943-951.
15. Mahajan A.A., Miniyar P.B., Patil A.S., Waghmare R.U., Patil J.J., Mohanraj K., Tiwari R.N. Separation, identification, and characterization of degradation products of erlotinib hydrochloride under ICH-recommended stress conditions by LC, LC-MS/TOF. J. Liq. Chromatogr. Relat. Technol. 2014, 38(5):629-639.
16. Mahnik S.N., Rizovski B., Fuerhacker M., Mader R.M. Determination of 5-fluorouracil in hospital effluents. Anal. Bioanal. Chem. 2004, 380(1):31-35.
17. Müller A., Schulz W., Ruck W.K.L., Weber W.H. A new approach to data evaluation in the non-target screening of organic trace substances in water analysis. Chemosphere 2011, 85(8):1211-1219.
18. Negreira N., Canosa P., Rodriguez I., Ramil M., Rubi E., Cela R. Study of some UV filters stability in chlorinated water and identification of halogenated by-products by gas chromatography-mass spectrometry. J. Chromatogr. A 2008, 1178(1-2):206-214.
19. Negreira N., Rodriguez I., Rodil R., Cela R. Assessment of benzophenone-4 reactivity with free chlorine by liquid chromatography quadrupole time-of-flight mass spectrometry. Anal. Chim. Acta 2012, 743:101-110.
20. Negreira N., Mastroianni N., López de Alda M., Barceló D. Multianalyte determination of 24 cytostatics and metabolites by liquid chromatography-electrospray-tandem mass spectrometry and study of their stability and optimum storage conditions in aqueous solution. Talanta 2013, 116(0):290-299.
21. Negreira N., López de Alda M., Barceló D. Study of the stability of 26 cytostatic drugs and metabolites in wastewater under different conditions. Sci. Total Environ. 2014, 482-483(0):389-398.
22. Negreira N., de Alda M.L., Barceló D. Degradation of the cytostatic etoposide in chlorinated water by liquid chromatography coupled to quadrupole-Orbitrap mass spectrometry: identification and quantification of by-products in real water samples. Sci. Total Environ. 2015, 506:36-45.
23. Nguyen K.-S.H., Neal J.W. First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biol. Targets Ther. 2012, 6:337.
24. Nussbaumer S., Bonnabry P., Veuthey J.-L., Fleury-Souverain S. Analysis of anticancer drugs: a review. Talanta 2011, 85(5):2265-2289.
25. Pluskal T., Castillo S., Villar-Briones A., Orešič M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 2010, 11(1):395.
26. Rodríguez-Cabo T., Paganini M., Carpinteiro I., Fontenla L., Rodríguez I., Pietrogrande M.C., Cela R. Liquid chromatography time-of-flight mass spectrometry evaluation of fungicides reactivity in free chlorine containing water samples. J. Mass Spectrom. 2013, 48(2):216-226.
27. Roig B., Marquenet B., Delpla I., Bessonneau V., Sellier A., Leder C., Thomas O., Bolek R., Kummerer K. Monitoring of methotrexate chlorination in water. Water Res. 2014, 57(0):67-75.
28. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63(1):11-30.
29. Soufan M., Deborde M., Legube B. Aqueous chlorination of diclofenac: kinetic study and transformation products identification. Water Res. 2012, 46(10):3377-3386.
30. Van Cutsem E., Vervenne W.L., Bennouna J., Humblet Y., Gill S., Van Laethem J.-L., Verslype C., Scheithauer W., Shang A., Cosaert J. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 2009, 27(13):2231-2237.
31. Verlicchi P., Galletti A., Petrovic M., Barceló D. Hospital effluents as a source of emerging pollutants: an overview of micropollutants and sustainable treatment options. J. Hydrol. 2010, 389(3-4):416-428.
32. Yin J., Shao B., Zhang J., Li K. A preliminary study on the occurrence of cytostatic drugs in hospital effluents in Beijing, China. Bull. Environ. Contam. Toxicol. 2010, 84(1):39-45.
33. Zhang J., Chang V.W.C., Giannis A., Wang J.-Y. Removal of cytostatic drugs from aquatic environment: a review. Sci. Total Environ. 2013, 445-446(0):281-298.
34. Zounkova R., Kovalova L., Blaha L., Dott W. Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. Chemosphere 2010, 81(2):253-260.